Trial Profile
Decreasing Risk of Recurrence by TAF in HCC Patients After Curative Treatment With Low HBV Viral Load
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- 05 Jul 2021 Status changed from not yet recruiting to recruiting.
- 06 Mar 2020 New trial record